Expression of lncRNA MEG3 in asthma with different phenotypes and its relationship with course of disease

Abstract

The purpose of this study was to explore the application value of lncRNA MEG3 in lung cancer. From March 2017 to March 2019, 119 asthma patients and 125 healthy people undergoing physical examination in the same period were selected as the research objects. The levels of lncRNA MEG3 in the peripheral blood of the two groups were compared, and the predictive value of MEG3 for asthma as well as the differences in different inflammatory phenotypes were analyzed. The expression of MEG3 was low in asthma patients (P<0.050), the diagnostic sensitivity and specificity for asthma were 79.83 and 66.40%, respectively (P<0.001), it was the lowest in mixed granulocytic asthma (P<0.050) and was negatively correlated with the course of disease (r=-0.666, P<0.001). Logistic regression analysis showed that course of disease, inflammatory phenotype and MEG3 were independent factors affecting recurrence of asthma (P<0.050). MEG3 was low expressed in asthma and had good predictive value for it; in mixed granulocytic asthma, its expression was the lowest and the course of disease was closely related. It might be the key to the diagnosis and treatment of asthma in the future.

The value of circulating long non‐coding RNA maternally expressed gene 3 as a predictor of higher acute respiratory distress syndrome risk and 28‐day mortality in sepsis patients

“…Another study illuminates that lncRNA MEG3 induces pulmonary microvascular endothelial cell apoptosis via the upregulation of caspase‐3 activity, reduction of Bcl‐2 level, and elevation of Bax in chronic obstructive pulmonary disease 11 . Meanwhile, lncRNA MEG3 has a good predictive value for disease risk of respiratory disease asthma 12 . In addition, lncRNA MEG3 upregulates IL‐1β abundance and exaggerates inflammatory responses in alveolar macrophages and lung epithelial cells, which is involved in the progression of sepsis, 13 and clinically, lncRNA MEG3 is proved to be associated with higher mortality risk in sepsis patients 14,15 .…”

“…[8][9][10][11] As an example, Zou et Meanwhile, lncRNA MEG3 has a good predictive value for disease risk of respiratory disease asthma. 12 In addition, lncRNA MEG3 upregulates IL-1β abundance and exaggerates inflammatory responses in alveolar macrophages and lung epithelial cells, which is involved in the progression of sepsis, 13 and clinically, lncRNA MEG3 is proved to be associated with higher mortality risk in sepsis patients. 14,15 While the clinical value of lncRNA MEG3 in sepsis-related ARDS is still unknown.…”

“…[8][9][10][11] Meanwhile, lncRNA MEG3 exhibited the potential as a biomarker for identifying disease risk and progression of respiratory disease asthma. 12 As for sepsis, lncRNA MEG3 modulates the pulmonary inflammatory responses to affect the initiation and progression of sepsis, and it displays the clinical implication in predicting prognosis in sepsis patients. [13][14][15] In view of above-mentioned facts, it was speculated that lncRNA MEG3 might exhibit the clinical value for identifying ARDS risk in sepsis patients, while relevant report is lack.…”

“…Recent researches reveal that lncRNA MEG3 is involved in the regulation of lung injury through regulating multiple inflammation‐relative signaling pathways and apoptosis‐related pathways such as caspase‐1 signaling and Janus kinases/signal transducer and activator of transcription proteins 8‐11 . Meanwhile, lncRNA MEG3 exhibited the potential as a biomarker for identifying disease risk and progression of respiratory disease asthma 12 . As for sepsis, lncRNA MEG3 modulates the pulmonary inflammatory responses to affect the initiation and progression of sepsis, and it displays the clinical implication in predicting prognosis in sepsis patients 13‐15 .…”

Investigation of circulating lncRNAs as potential biomarkers in chronic respiratory diseases

“…Some of them were also measured in our stage I study. In our discovery cohort we did not find differences in any comparison in the expression of TUG1, MALAT1, NEAT1 and MEG3 , all of them were found to be associated with asthma in different studies [ 30 – 33 ]. Although we measured the expression of these lncRNAs in the blood of only a small number of subjects (6 with mild-moderate, 6 with severe asthma and 6 controls), the lack of differences suggests that they are possibly not suitable for general asthma blood biomarkers.…”